The Company has further informed that due to unavoidable circumstances, the meeting of the Board of Directors of the Company as per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, will be held on October 28, 2026 at 3:30 PM instead of earlier declared on October 15, 2026 to consider, among others, audited financial statements of the Company for the year ended June 30, 2026.

As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 15, 2026 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2026.

The company has informed that the transfer of 16,04,603 shares of Navana Pharmaceuticals PLC held by Mr. Manzurul Islam (Sponsor), transferor, to Dr. Md. Jonaid Shafiq (Managing Director), transferee, has been completed outside the trading system of the Exchange other than by way of gift as per declaration disseminated on 04.08.2026.

The company has informed that pursuant to the direction of the Bangladesh Securities and Exchange Commission reference no: BSEC/ICSD/SRIC/2026-313/part-03/123: dated June 18, 2026, the 64th Meetings of the Board of Directors of Navana Pharmaceuticals PLC. have been postponed, with a direction to maintain the composition of the Board as it stood at the 63rd Board Meeting. Accordingly, as per the 63rd Board Meeting, the current members of the Board of Directors are as follows: Mrs. Saiqa Mazed-Chairman and Independent Director, Professor Dr. Md. Jonaid Shafiq-Managing Director, Dr. Sayeed Ahmed-Director, Mr. Javed Kaiser Ally-Director, Mrs. Tarana Ahmed-Director, Mrs. Masuma Parvin-Director, Mr. Khondaker Sabbir Mohammad Kabir (Nominee of Stratus Holdings Limited)-Director, Mr. Mohammad Arife Billah (Bar-At-Law)-Independent Director, Professor Mohammad Shofiqul Islam-Independent Director.

Dhaka Stock Exchange PLC. (DSE) has approved the transfer of 16,04,603 shares of Navana Pharmaceuticals PLC held by Mr. Manzurul Islam (Sponsor), transferor, to Dr. Md. Jonaid Shafiq (Managing Director), transferee, within next 30 working days with effect from August 02, 2026 outside the trading system of the Exchange other than by way of gift under Regulation 47(1)(b) of the Dhaka Stock Exchange (Listing) Regulations, 2015 as well as other applicable laws.

(Q3 Un-audited): EPS was Tk. 1.22 for Jan-March 2026 as against Tk. 1.01 for Jan-March 2025; EPS was Tk. 4.59 for July 2025-March 2026 as against Tk. 3.49 for July 2024-March 2025. Diluted EPS was Tk. 1.20 for Jan-March 2026 and Diluted EPS was Tk. 4.55 for July 2025-March 2026. NOCFPS was Tk. 15.44 for July 2025-March 2026 as against Tk. 10.22 for July 2024-March 2025. NAV per share was Tk. 49.53 as on March 31, 2026 and Tk. 45.29 as on June 30, 2025. (cont.1) Reasons for significant deviation in EPS and NOCFPS: Increment of Earnings per Share in the reporting period by 31.52% because of growth of Sales Revenue as well as optimum cost management policy & Net Operating Cash Flow per Share (NOCFPS) has increased to Tk. 15.44 from Tk. 10.22, due to cash received from the customers was higher than the cash payment for operation in the reporting period. (cont.2) 2. The Company has decided to proceed with a Foreign Loan Facilities for EUR 26,610,000.00 for 12 years from AKA Ausfuhrkredit-Gesellschaft mbH, Frankfurt, Germany, the sole arranger of which is KGMC Financial Service, Bangladesh. The Company has decided to avail the aforesaid facilities for expansion of its production facilities. The proposed financing shall remain subject to final approval from the concerned regulatory authorities & completion of due diligence.

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on June 03, 2026 at 3:00 pm to consider, among others, Un-Audited Financial Statements for the Third Quarter (Q3) period ended March 31, 2026.

The Company has informed that Mr. Lorens Shamol Mollick, FCS continues to legally hold his position as the official Company Secretary of Navana Pharmaceuticals PLC.

The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2025 to the respective shareholders.

The Company has informed that the Board of Directors has decided to appoint Mr. Md. Aminul Hoque Bhuiyan, ACS as the Acting Company Secretary of the company with immediate effect.